Ovarian Cancer

January 21st 2025

Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical interventions, increased adoption of minimally invasive techniques, and a greater focus on fertility preservation and sentinel lymph node procedures.

January 19th 2025

Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.

January 16th 2025

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.

January 14th 2025

Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.